Hexyl aminolevulinate (Cevira) for cervical high-grade squamous intraepithelial lesions
NIHR HSRIC
Record ID 32016000823
English
Authors' recommendations:
Cancer of the cervix usually takes many years to develop, and it often follows changes to the cells in the cervix called cervical intraepithelial lesions. These do not cause any harm themselves, but may need to be removed to prevent cancer in the future.
Hexyl aminolevulinate is a chemical that, when applied to the cervix and activated by a specific type of light, is used to treat cervical intraepithelial lesions. Current treatments include surgery or laser treatment.
Hexyl aminolevulinate is currently being studied to see how well it works and whether it is safe to use. If licensed, hexyl aminolevulinate will offer a new treatment for lesions of the cervix that lead to cancer.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/hexyl-aminolevulinate-cevira-for-cervical-high-grade-squamous-intraepithelial-lesions/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Aminolevulinic Acid
- Female
- Squamous Intraepithelial Lesions of the Cervix
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.